NCT04065165View on ClinicalTrials.gov

Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2020

Primary Completion Date

July 31, 2023

Study Completion Date

October 31, 2027

Conditions
Small Intestinal NETCarcinoid Heart Disease
Interventions
DRUG

Telotristat Ethyl

250 mg TID orally

DRUG

Lanreotide

120 mg Q4W deep subcutaneous injection in the superior external quadrant of the buttock or in the upper outer thigh

Sponsors

Collaborators (1)

Ipsen
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK